Linked Life Data

2853594

Source:http://linkedlifedata.com/resource/pubmed/id/2853594

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1989-5-3
pubmed:abstractText
While advances in the diagnosis and staging of SCLC have been made over the past decade, overall therapeutic results remain essentially unchanged. However, during this time period there have been major advances in understanding the biology of this tumor cell type. The recognition of considerable heterogeneity among SCLC cells may be of prognostic importance, while the demonstration of specific growth factors, including bombesin, for this tumor type may open up new means for endocrine therapy of lung carcinoma in vivo. Over the next 5-10 yr, studies of clinical trials using specific antibodies or analogs of bombesin-like growth factors in patients with SCLC will define more clearly the role of BLI and GRP in patients with this disease.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0077-8923
pubmed:author
pubmed:issnType
Print
pubmed:volume
547
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
303-9
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
Bombesin: a potent mitogen for small cell lung cancer.
pubmed:affiliation
Department of Medical Oncology, Mater Misericordiae Hospital, Dublin Ireland.
pubmed:publicationType
Journal Article